ENSYSCE BIOSCIENCES INC (ENSC) Stock News

NASDAQ:ENSC - Nasdaq - US2936024056 - Common Stock

8 +0.23 (+2.96%)

After market: 7.5256 -0.47 (-5.93%)

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

ENSC Latest News and Analysis

All

Press Releases

14 days ago - ACCESSWIRE

Ensysce Biosciences Issues Annual Shareholder Letter

a month ago - ACCESSWIRE

Ensysce Biosciences Regains Full Compliance with Nasdaq

a month ago - ACCESSWIRE

Ensysce Biosciences Announces Commercial Supplier for Breakthrough Overdose Protection Drug Product

2 months ago - ACCESSWIRE

Ensysce Biosciences Announces Strategic Partnership for the Development and Commercial Launch of PF614 and PF614-MPAR

2 months ago - Benzinga

Why Marvell Technology Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket

2 months ago - ACCESSWIRE

Ensysce Biosciences Announces 1-for-15 Reverse Stock Split

2 months ago - ACCESSWIRE

Ensysce Biosciences Completes Significant Milestone, Dosing First Subjects in Breakthrough Therapy PF614-MPAR Trial

2 months ago - Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

2 months ago - ACCESSWIRE

Ensysce Biosciences Reports Third Quarter 2024 Financial Results

3 months ago - ACCESSWIRE

Ensysce Biosciences Receives Positive Nasdaq Listing Determination

4 months ago - ACCESSWIRE

Ensysce Biosciences Announces Leadership Team’s Participation in the Annual Pain Therapeutics Summit

4 months ago - ACCESSWIRE

Ensysce Biosciences Provides Shareholder Update, Responds to Recent Shareholder Inquiries

4 months ago - ACCESSWIRE

Ensysce Biosciences Receives Notice from Nasdaq

4 months ago - ACCESSWIRE

Ensysce Biosciences Presenting at Upcoming Meetings

4 months ago - ACCESSWIRE

Ensysce Biosciences Submits Phase 3 Protocol to the FDA

4 months ago - ACCESSWIRE

Ensysce Biosciences Posts Video Updates from the IASP World Congress on Pain 2024